Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3001827 | Nutrition, Metabolism and Cardiovascular Diseases | 2015 | 10 Pages |
•Probiotic supplementation showed a greater reduction in serum TG and a greater increase in plasma apoA-V levels.•The TG-lowering effects of probiotic supplementation showed greater reductions in fatty acid primary amides and lysoPCs.•▵ TG negatively correlated with ▵ apoA-V in the probiotic group.•▵ TG positively correlated with ▵ FFA.•▵ FFA strongly and positively correlated with ▵ lysoPCs in the probiotic group.
Background and aimsThis study evaluated the triglyceride (TG)-lowering effects of consuming dual probiotic strains of Lactobacillus curvatus (L. curvatus) HY7601 and Lactobacillus plantarum (L. plantarum) KY1032 on the fasting plasma metabolome.Methods and resultsA randomized, double-blind, placebo-controlled study was conducted on 92 participants with hypertriglyceridemia but without diabetes. Over a 12-week testing period, the probiotic group consumed 2 g of powder containing 5 × 109 colony-forming units (cfu) of L. curvatus HY7601 and 5 × 109 cfu of L. plantarum KY1032 each day, whereas the placebo group consumed the same product without probiotics. Fasting plasma metabolomes were profiled using UPLC-LTQ-Orbitrap MS. After 12 weeks of treatment, the probiotic group displayed a 20% reduction (p = 0.001) in serum TGs and 25% increases (p = 0.001) in apolipoprotein A-V (apoA-V). At the 12-week follow-up assessment, the following 11 plasma metabolites were significantly reduced in the probiotic group than the placebo group: palmitoleamide, palmitic amide, oleamide, and lysophosphatidyl choline (lysoPC) containing C14:0, C16:1, C16:0, C17:0, C18:3, C18:2, C18:1, and C20:3. In the probiotic group, changes (▵) in TG were negatively correlated with ▵ apoA-V, which was positively correlated with ▵ FFA. In addition, ▵ FFA was strongly and positively correlated with ▵ lysoPCs in the probiotic group but not the placebo group.ConclusionsThe triglyceride-lowering effects of probiotic supplementation, partly through elevated apoA-V, in borderline to moderate hypertriglyceridemic subjects showed reductions in plasma metabolites, fatty acid primary amides and lysoPCs (NCT02215694; http://www.clinicaltrials.gov).Clinical trials: NCT02215694; http://www.clinicaltrials.gov